AzurRx clips its IPO price, but manages to get the job done
These days, completing a biotech IPO often means settling for less. And AzurRx BioPharma is lowering its sights to a micro offering worth about …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
